HK1257448A1 - 包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物 - Google Patents

包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物 Download PDF

Info

Publication number
HK1257448A1
HK1257448A1 HK18116683.8A HK18116683A HK1257448A1 HK 1257448 A1 HK1257448 A1 HK 1257448A1 HK 18116683 A HK18116683 A HK 18116683A HK 1257448 A1 HK1257448 A1 HK 1257448A1
Authority
HK
Hong Kong
Prior art keywords
ccl22
fragments
vaccine compositions
motif chemokine
chemokine
Prior art date
Application number
HK18116683.8A
Other languages
English (en)
Chinese (zh)
Inventor
Mads Hald Andersen
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Publication of HK1257448A1 publication Critical patent/HK1257448A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001142—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4236—Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK18116683.8A 2015-09-16 2016-09-16 包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物 HK1257448A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570591 2015-09-16
DKPA201570591 2015-09-16
PCT/DK2016/050301 WO2017045691A1 (en) 2015-09-16 2016-09-16 Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof

Publications (1)

Publication Number Publication Date
HK1257448A1 true HK1257448A1 (zh) 2019-10-18

Family

ID=57123753

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116683.8A HK1257448A1 (zh) 2015-09-16 2016-09-16 包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物

Country Status (8)

Country Link
US (3) US11298413B2 (enExample)
EP (1) EP3349785A1 (enExample)
JP (1) JP6924747B2 (enExample)
CN (2) CN116333088A (enExample)
AU (1) AU2016322506B2 (enExample)
HK (1) HK1257448A1 (enExample)
IL (1) IL257940B (enExample)
WO (1) WO2017045691A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016322506B2 (en) * 2015-09-16 2023-02-09 Io Biotech Aps Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
JP2021515797A (ja) * 2018-03-15 2021-06-24 アトッサ・セラピューティクス・インコーポレイテッド 免疫反応誘導のインサイツ方法
FR3084463B1 (fr) * 2018-07-30 2023-04-21 Francais Du Sang Ets Procede d'analyse des plaquettes d'un echantillon sanguin
MX2023001182A (es) * 2020-07-30 2023-02-22 Ct Inmunologia Molecular Uso de agentes depletantes del factor de crecimiento epidermico en el tratamiento de la enfermedad pulmonar obstructiva cronica.
WO2024168311A2 (en) * 2023-02-09 2024-08-15 The Brigham And Women’S Hospital, Inc. Autonomous gene circuits for therapy release

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5932703A (en) * 1995-06-07 1999-08-03 Icos Corporation Macrophage derived chemokine and chemokine analogs
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
US8563476B2 (en) * 2002-11-15 2013-10-22 Morehouse School Of Medicine Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders
EP1613308A4 (en) * 2003-03-27 2008-02-20 Lankenau Inst Medical Res CANCER TREATMENT METHODS
US20100113342A1 (en) * 2006-06-20 2010-05-06 Yount Nannette I Antimicrobial kinocidin compositions and methods of use
CN102088994B (zh) 2008-04-17 2014-06-25 海莱乌医院 基于吲哚胺2，3-双加氧酶的免疫疗法
WO2011006029A1 (en) * 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
WO2011139738A2 (en) 2010-04-28 2011-11-10 Tenx Biopharma, Inc. Therapies using zanolimumab to enhance the immune response
JP6259763B2 (ja) 2011-10-17 2018-01-10 ヘルレフ ホスピタルＨｅｒｌｅｖ Ｈｏｓｐｉｔａｌ Ｐｄ−ｌ１に基づく免疫療法
EP2800762B1 (en) * 2012-01-03 2018-01-03 The United States of America, as represented by the Secretary, Department of Health and Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
US20150359869A1 (en) 2012-08-15 2015-12-17 Cyvax, Inc. Methods and compositions for preventing a condition
JP6401702B2 (ja) * 2012-09-07 2018-10-10 ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ 炎症性肝疾患の診断のための方法および組成物
WO2014170389A1 (en) 2013-04-18 2014-10-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US10130454B2 (en) 2014-08-01 2018-11-20 Iowa State University Research Foundation, Inc. Vaccine delivery devices
AU2016322506B2 (en) 2015-09-16 2023-02-09 Io Biotech Aps Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof

Also Published As

Publication number Publication date
AU2016322506A1 (en) 2018-04-12
CN116333088A (zh) 2023-06-27
WO2017045691A9 (en) 2018-06-28
US12496333B2 (en) 2025-12-16
JP6924747B2 (ja) 2021-08-25
US20220339273A1 (en) 2022-10-27
NZ740930A (en) 2024-09-27
CN108472345A (zh) 2018-08-31
IL257940A (en) 2018-05-31
WO2017045691A1 (en) 2017-03-23
IL257940B (en) 2022-08-01
CA2998789A1 (en) 2017-03-23
US11298413B2 (en) 2022-04-12
CN108472345B (zh) 2023-05-23
US20230241191A9 (en) 2023-08-03
AU2016322506A9 (en) 2018-12-06
AU2016322506B2 (en) 2023-02-09
EP3349785A1 (en) 2018-07-25
US20220280624A1 (en) 2022-09-08
JP2018528960A (ja) 2018-10-04
US20190008939A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
WO2016011306A3 (en) Terminal modifications of polynucleotides
WO2016170348A8 (en) Sarna compositions and methods of use
WO2016011222A3 (en) Circular polynucleotides
SG11201609635XA (en) Novel high clarity low haze compositions
WO2015195531A3 (en) Syntac polypeptides and uses thereof
WO2014194034A3 (en) Novel metalloproteases
WO2015011694A3 (en) Isotopologues of smad7 antisense oligonucleotides
EP3359193A4 (en) NOVEL CARBOHYDRATIC ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
EP3262075A4 (en) Novel antibody binding to tfpi and composition comprising the same
HK1257448A1 (zh) 包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物
WO2015160928A3 (en) Isolated t cell receptors and methods of use therefor
WO2016108927A3 (en) Nitrification inhibitor compositions and methods for preparing the same
HK1255446A1 (zh) 分子质量保证方法在测序中的应用
WO2016079110A3 (en) Use of enzyme for cleaning
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
WO2016061555A3 (en) Novel small molecule anticancer agents
WO2017087917A3 (en) Bicarbonate biosensors, calcium biosensors, and uses thereof
WO2016141320A3 (en) Non-neuroinvasive viruses and uses thereof
EP3266315A4 (en) Gelling composition
GB201516975D0 (en) PARK2 as epigenetic marker for the identification of immune cells, in particular monocytes
WO2015104720A3 (en) Parenteral compositions of bendamustine
WO2018015810A3 (en) Multivirus-specific t cell immunotherapy
EP3636248B8 (en) Topical compositions containing cross-linked glycosaminoglycans
EP3244895A4 (en) Novel pharmaceutical composition